Corporate Statement

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Listening for Needs. Delivering Solutions. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future.

Investor Overview

News Releases

02 Dec '24
Net Proceeds to Reduce the Company's Net Debt by More Than 60% DUBLIN  , Dec. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has completed the previously announced sale of its Therakos business to CVC
18 Nov '24
– Poster evaluates potential impact of waiting until Day 4 (and after 12 doses of TERLIVAZ) before assessing outcomes in adult patients with HRS with rapid reduction in kidney function 1  – DUBLIN , Nov. 18, 2024 /PRNewswire/ -- Mallinckrodt plc , a global specialty pharmaceutical company, today
14 Nov '24
DUBLIN , Nov. 14, 2024 /PRNewswire/ -- Mallinckrodt plc , a global specialty pharmaceutical company, today announced that Siggi Olafsson , President and Chief Executive Officer, will present at Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:30 a.m. GMT / 4:30 a.m. ET .
go back to the top of the page